RATIONALE: Loss of insulin action in the endothelium can cause endothelial dysfunction and atherosclerosis. Hyperglycemia and elevated fatty acids induced by diabetes mellitus can activate protein kinase C-β isoforms and selectively inhibit insulin signaling via phosphatidylinositol 3-kinase/Akt pathway to inhibit the activation of endothelial nitric oxide synthase and metabolic actions. OBJECTIVE: To demonstrate that overexpressing protein kinase C-β2 isoform in endothelial cells can cause selective insulin resistance and exacerbate atherosclerosis in the aorta. METHODS AND RESULTS: Protein kinase C-β2 isoform was overexpressed in endothelial cells using a promoter of vascular endothelial cell cadherin. These mice were cross-bred with apoE-/- mice [Tg (Prkcb)apoE-/-]. On a Western diet, Tg(Prkcb)apoE-/- and apoE-/- mice did not differ in systemic insulin sensitivity, glucose tolerance, plasma lipid, or blood pressure. Insulin action in endothelial cells and femoral artery from Tg(Prkcb)apoE-/- mice was impaired by ≈40% with respect to Akt/endothelial nitric oxide synthase activation, and leukocyte-endothelial cell binding increased in cultured lung endothelial cells from Tg(Prkcb)apoE-/- mice compared with that from apoE-/- mice. Basal and angiotensin-stimulated big endothelin-1 levels were elevated in Tg(Prkcb)apoE-/- mice compared with apoE-/- mice. The severity of atherosclerosis in the aorta from Tg(Prkcb)apoE-/- mice increased by ≈70% as measured by en face fat staining and plaque content of the number of smooth muscle cells, macrophages, and extracellular matrix. CONCLUSIONS: Specific protein kinase C-β2 activation in the endothelial cells caused dysfunction and accelerated atherosclerosis because of loss of insulin-stimulated Akt/endothelial nitric oxide synthase activation and angiotensin-induced increases in endothelin-1 expression.
RATIONALE: Loss of insulin action in the endothelium can cause endothelial dysfunction and atherosclerosis. Hyperglycemia and elevated fatty acids induced by diabetes mellitus can activate protein kinase C-β isoforms and selectively inhibit insulin signaling via phosphatidylinositol 3-kinase/Akt pathway to inhibit the activation of endothelial nitric oxide synthase and metabolic actions. OBJECTIVE: To demonstrate that overexpressing protein kinase C-β2 isoform in endothelial cells can cause selective insulin resistance and exacerbate atherosclerosis in the aorta. METHODS AND RESULTS: Protein kinase C-β2 isoform was overexpressed in endothelial cells using a promoter of vascular endothelial cell cadherin. These mice were cross-bred with apoE-/- mice [Tg (Prkcb)apoE-/-]. On a Western diet, Tg(Prkcb)apoE-/- and apoE-/- mice did not differ in systemic insulin sensitivity, glucose tolerance, plasma lipid, or blood pressure. Insulin action in endothelial cells and femoral artery from Tg(Prkcb)apoE-/- mice was impaired by ≈40% with respect to Akt/endothelial nitric oxide synthase activation, and leukocyte-endothelial cell binding increased in cultured lung endothelial cells from Tg(Prkcb)apoE-/- mice compared with that from apoE-/- mice. Basal and angiotensin-stimulated big endothelin-1 levels were elevated in Tg(Prkcb)apoE-/- mice compared with apoE-/- mice. The severity of atherosclerosis in the aorta from Tg(Prkcb)apoE-/- mice increased by ≈70% as measured by en face fat staining and plaque content of the number of smooth muscle cells, macrophages, and extracellular matrix. CONCLUSIONS: Specific protein kinase C-β2 activation in the endothelial cells caused dysfunction and accelerated atherosclerosis because of loss of insulin-stimulated Akt/endothelial nitric oxide synthase activation and angiotensin-induced increases in endothelin-1 expression.
Entities:
Keywords:
atherosclerosis; endothelium; insulin resistance; protein kinase C
Authors: Eva Chou; Izumi Suzuma; Kerrie J Way; Darren Opland; Allen C Clermont; Keiko Naruse; Kiyoshi Suzuma; Nancy L Bowling; Chris J Vlahos; Lloyd Paul Aiello; George L King Journal: Circulation Date: 2002-01-22 Impact factor: 29.690
Authors: J Y Park; N Takahara; A Gabriele; E Chou; K Naruse; K Suzuma; T Yamauchi; S W Ha; M Meier; C J Rhodes; G L King Journal: Diabetes Date: 2000-07 Impact factor: 9.461
Authors: P J Kuhlencordt; R Gyurko; F Han; M Scherrer-Crosbie; T H Aretz; R Hajjar; M H Picard; P L Huang Journal: Circulation Date: 2001-07-24 Impact factor: 29.690
Authors: M I Cybulsky; K Iiyama; H Li; S Zhu; M Chen; M Iiyama; V Davis; J C Gutierrez-Ramos; P W Connelly; D S Milstone Journal: J Clin Invest Date: 2001-05 Impact factor: 14.808
Authors: Tamotsu Yokota; Ronald C Ma; Joong-Yeol Park; Keiji Isshiki; Konstantinos B Sotiropoulos; Ravi K Rauniyar; Karin E Bornfeldt; George L King Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Kyoungmin Park; Qian Li; Net Daş Evcimen; Christian Rask-Madsen; Yasutaka Maeda; Ernesto Maddaloni; Hisashi Yokomizo; Takanori Shinjo; Ronald St-Louis; Jialin Fu; Daniel Gordin; Mogher Khamaisi; David Pober; Hillary Keenan; George L King Journal: Arterioscler Thromb Vasc Biol Date: 2017-11-21 Impact factor: 8.311
Authors: Guy Eelen; Pauline de Zeeuw; Lucas Treps; Ulrike Harjes; Brian W Wong; Peter Carmeliet Journal: Physiol Rev Date: 2018-01-01 Impact factor: 37.312